Observational studyMedicine2026
Association between plasma ceramide levels and endothelial dysfunction in patients with acute coronary syndrome: A prospective observational study.
Observational study in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ceramides are bioactive lipids that contribute to endothelial dysfunction (ED) by promoting inflammation and oxidative stress. However, whether ceramide levels are linked to peripheral microvascular endothelial function in patients with acute coronary syndrome (ACS) is not well understood. We conducted a prospective observational study of 80 ACS patients undergoing percutaneous coronary intervention at a single center. Peripheral endothelial function was assessed using the EndoPAT2000® system. ED was defined as a reactive hyperemia index <1.67. Plasma ceramide species were quantified using high-performance liquid chromatography coupled with tandem mass spectrometry. The patients were stratified by ED status, ceramide level tertiles, and subgroup clinical characteristics. Multivariate logistic regression was used to determine the odds ratios and 95% confidence intervals for ED. ED was present in 57.5% of the patients. No significant differences were observed in age, gender, traditional cardiovascular risk factors, or lipid parameters between ED and non-ED groups. Among the 7 ceramide species analyzed, cer (d18:1/24:0) was significantly elevated in the ED group (P = .045). Cer (d18:1/24:0) was independently associated with ED (odds ratios = 2.83; 95% confidence intervals: 1.08-7.44; P = .034). Reactive hyperemia index values declined across tertiles of cer (d18:1/24:0) (P for trend = .03). Among patients on standard medications such as statins, β-blockers, or angiotensin-converting enzyme inhibitors (ACEI)/ARB) therapy, cer (d18:1/24:0) levels were still markedly higher in those with ED than in those without (all P < .05). Plasma cer (d18:1/24:0) is independently associated with impaired endothelial function in ACS patients. Its elevated levels in patients with ED despite receiving standard cardiovascular therapies suggest its potential role in residual ED and indicate its value as a candidate biomarker for vascular risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.